Latest period
$1.50B
YoY change
-28.0%
5Y CAGR
+28.0%
Peak year (2024)
$2.27B
Latest annual
$1.63B
Total Equity history chart for Revolution Medicines (RVMD) from 2017 to 2025
Latest: $1.63B
Total Equity growth chart for Revolution Medicines (RVMD) from 2017 to 2025
Latest: -28.0%
Total Equity history table for Revolution Medicines (RVMD) from 2017 to 2025
| 2025 | $1.63B | -28.0% | −$633.91M | ||
| 2024 | $2.27B | +24.0% | +$439.01M | ||
| 2023 | $1.83B | +166.5% | +$1.14B | ||
| 2022 | $685.19M | +13.7% | +$82.62M | ||
| 2021 | $602.57M | +26.9% | +$127.89M | ||
| 2020 | $474.68M | +211.2% | +$322.14M | ||
| 2019 | $152.53M | +57.8% | +$55.88M | ||
| 2018 | $96.66M | +2033.3% | +$92.13M | ||
| 2017 | $4.53M | — | — |
- 2025$1.63B-28.0%
- 2024$2.27B+24.0%
- 2023$1.83B+166.5%
- 2022$685.19M+13.7%
- 2021$602.57M+26.9%
- 2020$474.68M+211.2%
- 2019$152.53M+57.8%
- 2018$96.66M+2033.3%
- 2017$4.53M—
Total Equity values are taken from Revolution Medicines's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at Revolution Medicines (RVMD)
According to Revolution Medicines's latest reported financial statements, the company's latest reported total equity is $1.50B. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Revolution Medicines (RVMD) reported total equity of $1.63B – declined 28.0% year-over-year.
Across 2020–2025 (5 years), Revolution Medicines total equity produced a CAGR of +28.0% – with mixed annual results across the window.
Between 2024 and 2025, Revolution Medicines total equity declined 28.0%, falling from $2.27B to $1.63B.
$2.27B stands as the all-time-high annual total equity, posted in 2024, against a low of $4.53M during 2017.
Revolution Medicines Total Equity by Year
Revolution Medicines Total Equity 2025: $1.63B
In 2025, Revolution Medicines reported total equity of $1.63B, declined 28.0% below 2024.
Revolution Medicines Total Equity 2024: $2.27B
Revolution Medicines total equity in 2024 was $2.27B, grew 24.0% from 2023. This figure represents the highest annual value in the available history.
Revolution Medicines Total Equity 2023: $1.83B
2023's total equity for Revolution Medicines came in at $1.83B, surged 166.5% from 2022.
Revolution Medicines Total Equity 2022: $685.19M
Revolution Medicines posted total equity of $685.19M in 2022, grew 13.7% from 2021.
Revolution Medicines Total Equity 2021: $602.57M
Revolution Medicines total equity in 2021 was $602.57M.
See more financial history for Revolution Medicines (RVMD).
Sector peers by Total Equity
Healthcare peers of Revolution Medicines (RVMD), ranked by their latest total equity
| $94.11B | |
| $81.54B | |
| $52.61B | |
| $48.67B | |
| $30.52B | |
| $26.54B | |
| $8.66B | |
| −$3.27B |
- $94.11B
- $81.54B
- $52.61B
- $48.67B
- $30.52B
- $26.54B
- $8.66B
- −$3.27B
Frequently asked questions
Revolution Medicines (RVMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation